Article Contents ::
- 1 The Brand Name ONCOMIDE Has Generic Salt :: Cyclophosphamide
- 2 ONCOMIDE Is From Company Khandelwal Priced :: Rs. 32
- 3 ONCOMIDE have Cyclophosphamide is comes under Sub class Anti Neoplastic Agents of Main Class Anti Neoplastic Agents
- 4 Main Medicine Class:: Anti Neoplastic Agents Sub Medicine Class :: Anti Neoplastic Agents
- 5 Disclaimer ::
- 6 The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.
The Brand Name ONCOMIDE Has Generic Salt :: Cyclophosphamide
ONCOMIDE Is From Company Khandelwal Priced :: Rs. 32
ONCOMIDE have Cyclophosphamide is comes under Sub class Anti Neoplastic Agents of Main Class Anti Neoplastic Agents
Main Medicine Class:: Anti Neoplastic Agents Sub Medicine Class :: Anti Neoplastic Agents
| Salt Name : OR Generic Name | Form | Price : MRP /Probable | Packing | ||
| Cyclophosphamide | INJ | Rs. 32 | 1 |
| Brand Name | Company / Manufacturers | Strength | Unit | Price / 1 |
| ONCOMIDE | Khandelwal | 200MG | 1 | Rs. 32 |
| Company Brand Name | Salt Combination | Main Medical Class | Sub Medical Class |
| From Khandelwal :: ONCOMIDE | Cyclophosphamide | Anti Neoplastic Agents | Anti Neoplastic Agents |
Indications for Drugs ::
Bone marrow transplantation, malignancies, lymphomas, brain cancer, leukemia, systemic lupus erythematosus, minimal change disease, severe rheumatoid arthritis, wegener’s granulomatosis, multiple sclerosis, multiple myeloma, carcinoma of the breast, ovarian carcinoma, neuroblastoma, retinoblastoma.
Drug Dose ::
Adult: PO Part of the conditioning regimen in patients undergoing bone marrow transplantation 60 mg/kg/day for 2 days. Malignancies Low dose regimen: 2-6 mg/kg/wk in divided doses. IV Malignancies Moderate dose regimen: 10-15 mg/kg/wk; high dose regimen: 20-40 mg/kg given every 10-20 days.
Contraindication ::
Bladder haemorrhage. Patients with bone-marrow aplasia, acute infection, drug- or radiation-induced urothelial toxicity. Porphyria. Pregnancy and lactation.
Drug Precautions ::
Blood disorders. Elderly or debilitated patients. Diabetic patients. Renal or hepatic impairment or who have gone adrenaloctomy. Previous treatment with x-ray or cytotoxic agents. Monitor haematological profile and presence of RBCs in urine regularly. Maintain adequate hydration and frequent micturition to reduce the risk of cystitis.
Drug Side Effects ::
Congestive heart failure; leucopenia; poor wound healing; anorexia. Nausea, vomiting; alopoecia; oral mucosal ulceration; thrombocytopenia, anaemia; nonhaemorrhagic cystitis and/or fibrosis of the bladder; gonadal suppression, ovarian or skin and nail pigmentation, dermatitis, jaundice. Potentially Fatal: Myelosuppression; haemorrhagic cystitis; interstitial pulmonary fibrosis; tachyarrhythmias and intractable heart failure (high doses). Increased risk of developing acute leukaemias.
Pregnancy category ::
4
Drug Mode of Action ::
Cyclophosphamide is a prodrug which is converted in the body to the active metabolites. It acts at any stage of the cell cycle but its main action is blockage at the G2 stage. It arrests cell division by alkylating the DNA in a dose-dependent manner. It also exerts immunosuppressive effects possibly due to a cytotoxic effect on lymphocytes.
Drug Interactions ::
Chronic high-dose administration of phenobarbital can increase the metabolism and leukopaenic activity of cyclophosphamide. Doxorubicin and daunorubicin increase risk of cardiotoxicity. Allopurinol may increase risk of bone marrow toxicity while chloramphenicol may increase the serum T1/2 of cyclophosphamide. Potentially Fatal: Serious toxicity when combined with other myelotoxic drugs or radiotherapy.
